Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

v3.24.3
Subsequent Events
9 Months Ended
Sep. 30, 2024
Subsequent Events  
Subsequent Events

14. Subsequent Events

Twist Bioscience Royalty Purchase Agreement

On October 21, 2024, the Company entered into a royalty purchase agreement with Twist Bioscience Corporation (“Twist Bioscience”). Under the terms of the agreement, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, sublicense income, and option exercise payments) related to Twist Bioscience’s 60-plus early-stage programs across 30 partners for a $15.0 million upfront payment. The Company is eligible to receive up to $0.5 billion in milestone payments and a 50% share of up to low single-digit royalties on future commercial sales.